Memo Therapeutics Ltd closes Series A2-Second Tranche

24. July 2019

Memo Therapeutics Ltd, is a biotech spin-off company from ETH Zurich and innovator in the field of antibody discovery and immune repertoire analysis.

Memo Therapeutics Ltd was advised in all legal matters with regard to the Series A2-Financing Round (Second Tranche) by Bader Gnehm & Partner. The team was led by Oliver Gnehm (Partner) and furthermore included Denis A. Parvex (Associate).